Related Experiment Video
Updated: Jul 13, 2026
09:57
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery
Sanjay K Jain1, Yashwant Gupta, Anekant Jain
1Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar, India. drskjainsagar@rediffmail.com
Drug Delivery
|August 19, 2007
Summary
Multivesicular liposomes (MVLs) enhance celecoxib solubility and provide sustained anti-inflammatory effects. These novel drug delivery systems offer prolonged therapeutic action compared to conventional methods.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Nanotechnology
Background:
- Celecoxib's conventional therapy is limited by solubility issues.
- Drug delivery systems aim to improve therapeutic efficacy and patient compliance.
- Liposomes offer a versatile platform for encapsulating various therapeutic agents.
Purpose of the Study:
- To develop and characterize multivesicular liposomes (MVLs) for sustained delivery of celecoxib.
- To enhance celecoxib's aqueous solubility using beta-cyclodextrin complexation.
- To evaluate the in vitro and in vivo performance of the developed celecoxib-loaded MVLs.
Main Methods:
- Celecoxib-beta-cyclodextrin inclusion complexes were prepared.
- Multivesicular liposomes (MVLs) and multilamellar vesicles (MLVs) were formulated using distinct methods.
- Formulations were characterized for size, encapsulation efficiency, and in vitro drug release.
- In vivo anti-inflammatory activity was assessed using the carrageenan-induced rat paw edema model.
Main Results:
- Phase solubility studies confirmed increased celecoxib aqueous solubility with beta-cyclodextrin.
- In vitro studies showed sustained release from MVLs over 120 hours compared to MLVs (48 hours).
- In vivo studies demonstrated prolonged anti-inflammatory effects with MVLs, maintaining 40.7% paw volume reduction after 24 hours.
Conclusions:
- Multivesicular liposomes are effective for sustained delivery of celecoxib-beta-cyclodextrin inclusion complexes.
- The developed MVL formulation offers prolonged anti-inflammatory action, overcoming limitations of conventional celecoxib therapy.
- This approach holds promise for enhanced therapeutic outcomes in inflammatory conditions.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...